Frontline Therapies Archives

April 9, 2025

First-line Atezolizumab-Venetoclax-Obinutuzumab for CLL

Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.

March 5, 2025

First-Line Pirtobrutinib-Venetoclax-Obinutuzumab for CLL

The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.

January 28, 2025

Sonrotoclax and Zanubrutinib as a Frontline CLL Treatment

The combination of sonrotoclax and zanubrutinib was well-tolerated and produced high rates of undetectable disease in patients with treatment-naïve CLL.

January 10, 2025

AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL

The AMPLIFY trial of acalabrutinib plus venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy.

December 2, 2024

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.

August 16, 2024

First-Line Treatment Outcomes in Patients with SLL

Researchers studied first-line treatment with targeted therapies for patients with small lymphocytic lymphoma (SLL) and found they had durable remissions.

August 8, 2024

First-Line Venetoclax Combination Therapies for CLL

The GAIA clinical trial tested various combination therapies using venetoclax to evaluate their efficacy in treating chronic lymphocytic leukemia (CLL).

May 1, 2024

Sonrotoclax Plus Zanubrutinib for Treatment-Naïve CLL and SLL

Early data on combination sonrotoclax plus zanubrutinib for previously untreated CLL / SLL is very promising.

April 3, 2024

Time-Limited Ibrutinib Plus Venetoclax for CLL

A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Frontline Therapies

First-line Atezolizumab-Venetoclax-Obinutuzumab for CLL

First-Line Pirtobrutinib-Venetoclax-Obinutuzumab for CLL

Sonrotoclax and Zanubrutinib as a Frontline CLL Treatment

AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

First-Line Treatment Outcomes in Patients with SLL

First-Line Venetoclax Combination Therapies for CLL

Sonrotoclax Plus Zanubrutinib for Treatment-Naïve CLL and SLL

Time-Limited Ibrutinib Plus Venetoclax for CLL

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT